NCT06149013 is a NA clinical trial of MindAhead Active in Mild Cognitive Impairment, sponsored by MindAhead UG.

Who is sponsoring NCT06149013?

NCT06149013 is sponsored by MindAhead UG.

What drugs are being tested in NCT06149013?

Interventions in NCT06149013: MindAhead Active, Treatment-as-usual.

What condition does NCT06149013 study?

NCT06149013 studies Mild Cognitive Impairment, Mild Dementia.

Is NCT06149013 still recruiting?

NCT06149013 is currently completed. Last updated 13 November 2024.

Last reviewed 2024-11-13 · How we verify

NCT06149013

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of MindAhead's Digital Behavioral Activation Therapy in Adults with MCI or Mild Dementia

Completed NA Last updated 13 November 2024

What this trial tests

NA trial testing MindAhead Active in Mild Cognitive Impairment in 50 participants. Completed in 31 October 2024.

Timeline

21 December 2023

Primary endpoint
31 October 2024

31 October 2024

Quick facts

Lead sponsor	MindAhead UG
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	50
Start date	21 December 2023
Primary completion	31 October 2024
Estimated completion	31 October 2024
Sites	1 location across Germany

Drugs / interventions tested

MindAhead Active
Treatment-as-usual

Conditions studied

Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
Mild Dementia — all drugs for Mild Dementia →

Sponsor

MindAhead UG

Who can join

50 and older, any sex, with Mild Cognitive Impairment or Mild Dementia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot study investigates effects of a digital behavioral activation therapy in treating patients with mild cognitive impairment and mild dementia, applying a randomized controlled parallel group design. The primary goal is to estimate effect sizes for a larger trial. A further aim is to investigate the feasibility of study procedures and to validate new questionnaire scores. Primary outcomes are the change in the patients' quality of life and in their overall activity level.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Mild Cognitive Impairment

Currently open trials in the same condition.

NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06149013 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MindAhead UG
Last refreshed: 13 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06149013.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing